Financhill
Sell
48

RYTM Quote, Financials, Valuation and Earnings

Last price:
$58.21
Seasonality move :
54.9%
Day range:
$60.00 - $65.46
52-week range:
$35.17 - $68.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.38x
P/B ratio:
203.89x
Volume:
1.1M
Avg. volume:
879K
1-year change:
56.01%
Market cap:
$3.9B
Revenue:
$130.1M
EPS (TTM):
-$2.81

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RYTM
Rhythm Pharmaceuticals
$40.2M -$0.68 48.98% -14.55% $82.08
ALT
Altimmune
$560 -$0.34 -88.8% -6.45% $22.38
CPRX
Catalyst Pharmaceuticals
$131.1M $0.53 14.53% 52.49% $34.00
CYTK
Cytokinetics
$2.6M -$1.36 466.02% -8.16% $74.52
GERN
Geron
$48.5M -$0.04 5681.41% -56% $3.81
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $800.13
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RYTM
Rhythm Pharmaceuticals
$60.72 $82.08 $3.9B -- $0.00 0% 27.38x
ALT
Altimmune
$5.80 $22.38 $446.7M -- $0.00 0% 20,593.10x
CPRX
Catalyst Pharmaceuticals
$22.76 $34.00 $2.8B 14.50x $0.00 0% 5.36x
CYTK
Cytokinetics
$32.48 $74.52 $3.9B -- $0.00 0% 195.86x
GERN
Geron
$1.26 $3.81 $802.5M -- $0.00 0% 7.17x
REGN
Regeneron Pharmaceuticals
$547.67 $800.13 $59.1B 13.94x $0.88 0.16% 4.44x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RYTM
Rhythm Pharmaceuticals
-- 1.841 -- 2.97x
ALT
Altimmune
-- 2.792 -- 12.90x
CPRX
Catalyst Pharmaceuticals
-- 0.175 -- 5.85x
CYTK
Cytokinetics
168.01% 0.673 13.74% 5.89x
GERN
Geron
30.68% 1.799 11.72% 6.84x
REGN
Regeneron Pharmaceuticals
6.33% 0.973 2.89% 3.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RYTM
Rhythm Pharmaceuticals
$29.1M -$47M -116.92% -116.92% -134.57% -$40.4M
ALT
Altimmune
-- -$24.9M -61.21% -61.21% -463580% -$18.3M
CPRX
Catalyst Pharmaceuticals
$123.5M $63.4M 29.43% 29.43% 44.81% $60M
CYTK
Cytokinetics
-$98.3M -$155.6M -121.06% -- -8766.94% -$137.3M
GERN
Geron
$38.4M -$16.7M -35.11% -46.58% -29.38% -$48M
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M

Rhythm Pharmaceuticals vs. Competitors

  • Which has Higher Returns RYTM or ALT?

    Altimmune has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -463600%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Altimmune's return on equity of -61.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
    ALT
    Altimmune
    -- -$0.33 $123.5M
  • What do Analysts Say About RYTM or ALT?

    Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 31.62%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 285.78%. Given that Altimmune has higher upside potential than Rhythm Pharmaceuticals, analysts believe Altimmune is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
    ALT
    Altimmune
    5 1 0
  • Is RYTM or ALT More Risky?

    Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Altimmune has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.05%.

  • Which is a Better Dividend Stock RYTM or ALT?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or ALT?

    Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are larger than Altimmune quarterly revenues of $5K. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Altimmune's net income of -$23.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 27.38x versus 20,593.10x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
    ALT
    Altimmune
    20,593.10x -- $5K -$23.2M
  • Which has Higher Returns RYTM or CPRX?

    Catalyst Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of 40.12%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
    CPRX
    Catalyst Pharmaceuticals
    87.34% $0.45 $794.3M
  • What do Analysts Say About RYTM or CPRX?

    Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 31.62%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 49.39%. Given that Catalyst Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Catalyst Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is RYTM or CPRX More Risky?

    Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

  • Which is a Better Dividend Stock RYTM or CPRX?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or CPRX?

    Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 27.38x versus 5.36x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
    CPRX
    Catalyst Pharmaceuticals
    5.36x 14.50x $141.4M $56.7M
  • Which has Higher Returns RYTM or CYTK?

    Cytokinetics has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -10220.14%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
    CYTK
    Cytokinetics
    -6223.05% -$1.36 $391.7M
  • What do Analysts Say About RYTM or CYTK?

    Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 31.62%. On the other hand Cytokinetics has an analysts' consensus of $74.52 which suggests that it could grow by 129.45%. Given that Cytokinetics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Cytokinetics is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
    CYTK
    Cytokinetics
    10 3 0
  • Is RYTM or CYTK More Risky?

    Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

  • Which is a Better Dividend Stock RYTM or CYTK?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or CYTK?

    Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are larger than Cytokinetics quarterly revenues of $1.6M. Rhythm Pharmaceuticals's net income of -$49.5M is higher than Cytokinetics's net income of -$161.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 27.38x versus 195.86x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
    CYTK
    Cytokinetics
    195.86x -- $1.6M -$161.4M
  • Which has Higher Returns RYTM or GERN?

    Geron has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -50.09%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Geron's return on equity of -46.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
    GERN
    Geron
    96.96% -$0.03 $387M
  • What do Analysts Say About RYTM or GERN?

    Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 31.62%. On the other hand Geron has an analysts' consensus of $3.81 which suggests that it could grow by 202.58%. Given that Geron has higher upside potential than Rhythm Pharmaceuticals, analysts believe Geron is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
    GERN
    Geron
    4 3 0
  • Is RYTM or GERN More Risky?

    Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

  • Which is a Better Dividend Stock RYTM or GERN?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or GERN?

    Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Geron quarterly revenues of $39.6M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Geron's net income of -$19.8M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 27.38x versus 7.17x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
    GERN
    Geron
    7.17x -- $39.6M -$19.8M
  • Which has Higher Returns RYTM or REGN?

    Regeneron Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of 26.7%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About RYTM or REGN?

    Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 31.62%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 46.1%. Given that Regeneron Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
    REGN
    Regeneron Pharmaceuticals
    13 5 0
  • Is RYTM or REGN More Risky?

    Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

  • Which is a Better Dividend Stock RYTM or REGN?

    Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RYTM or REGN?

    Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 27.38x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
    REGN
    Regeneron Pharmaceuticals
    4.44x 13.94x $3B $808.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 7.5% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 8.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock